Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation
A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.
Hodgkin Lymphoma|Non-hodgkin Lymphoma
BIOLOGICAL: AB-205
Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5, 24 hours
Occurrence of adverse events grade ≥ 3 as assessed by CTCAEv5, 100 days|Severity and duration of grade ≥ 3 mucosal toxicities including oropharyngeal mucositis, nausea, vomiting, and/or diarrhea., Day 0 to hospital discharge|Time to neutrophil engraftment, First of three consecutive days after ASCT of absolute neutrophil count (ANC) > 500/μL|Time to platelet engraftment, First of seven consecutive days after ASCT of platelet count ≥ 20,000/μL without transfusion support|Time to lymphoid recovery, 14, 28 and 100 days post-ASCT|Progression-free survival, 100 and 365 days post-ASCT|Non-relapse mortality, 100 and 365 days post-ASCT|Overall survival, 100 and 365 days post-ASCT
A phase 1, open label, multi-center trial of AB-205 in adults with Hodgkin or non-Hodgkin lymphoma who are in chemo-sensitive remission undergoing high-dose therapy, with or without radiation, and autologous stem cell transplantation (HDT-ASCT). Subjects will receive AB-205 infusion following autologous stem cell transfusion on Day 0.